Aytu BioScience Revenue and Competitors

Denver, CO USA

Location

$32M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Aytu BioScience's estimated annual revenue is currently $36.2M per year.(i)
  • Aytu BioScience's estimated revenue per employee is $251,250
  • Aytu BioScience's total funding is $32M.

Employee Data

  • Aytu BioScience has 144 Employees.(i)
  • Aytu BioScience grew their employee count by -3% last year.

Aytu BioScience's People

NameTitleEmail/Phone
1
Co-Founder & CEOReveal Email/Phone
2
Chairman & CEOReveal Email/Phone
3
VP OperationsReveal Email/Phone
4
VP and Corporate ControllerReveal Email/Phone
5
VP Regulatory Affairs and Quality AssuranceReveal Email/Phone
6
EVP & Corporate OperationsReveal Email/Phone
7
R&D DirectorReveal Email/Phone
8
Sr. Director, Organizational Insights and AnalyticsReveal Email/Phone
9
Director, MarketingReveal Email/Phone
10
Chief Commercial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6M300%N/AN/A
#2
$9.6M48-6%N/AN/A
#3
$3.4M17-23%N/AN/A
#4
$195M1280%$121.4MN/A
#5
$5.8M29-19%N/AN/A
#6
$5.8M29-15%N/AN/A
#7
$5.8M2921%N/AN/A
#8
$4.2M42-11%$138MN/A
#9
$4.4M22-8%N/AN/A
#10
$19.9M9922%N/AN/A
Add Company

What Is Aytu BioScience?

Aytu BioScience, Inc. is a specialty healthcare company focused on developing treatments for urological and related conditions. The Company is currently completing Phase 3 clinical development for its lead therapeutic candidate Zertane™, an orally disintegrating tablet (ODT) formulated specifically for the on-demand treatment of premature ejaculation (PE). The Company's therapeutic pipeline is supported in part by its first-in-class RedoxSYS® System, which provides the only complete assessment of patients' redox status and enables identification of a broad variety of disorders where redox is implicated. Clinical studies are underway utilizing the RedoxSYS system in male fertility. The Company also recently acquired and is commercializing FDA-approved ProstaScint® (capromab pendetide), a radio-labeled monoclonal antibody, that targets Prostate Specific Membrane Antigen (PSMA), a protein uniquely expressed by prostate tissue. The Company's strategy is to develop its core therapeutic and diagnostic assets while building an innovative pipeline of established marketed products and late-stage development assets.

keywords:N/A

$32M

Total Funding

144

Number of Employees

$36.2M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Aytu BioScience News

2022-04-17 - Aytu BioPharma (NASDAQ:AYTU) Rating Lowered to Hold at Zacks ... Defense World

Aytu BioPharma (NASDAQ:AYTU) Rating Lowered to Hold at Zacks ... Defense World

2022-04-17 - Axsome and Aytu's Positive Day with the FDA BioSpace

Axsome and Aytu's Positive Day with the FDA BioSpace

2022-04-17 - Aytu BioScience (AYTU) Granted FDA Fast Track Designation for ... StreetInsider

Aytu BioScience (AYTU) Granted FDA Fast Track Designation for ... StreetInsider

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$42.8M144-11%N/A
#2
$28.5M14426%N/A
#3
$17990M1463%$6.3B
#4
$35.3M146-6%N/A
#5
$24.3M1471%N/A